vs
Bioventus Inc.（BVS）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是Bioventus Inc.的1.0倍（$162.6M vs $157.9M），Ribbon Communications Inc.净利率更高（54.8% vs 9.3%，领先45.4%），Bioventus Inc.同比增速更快（2.8% vs -10.3%），过去两年Bioventus Inc.的营收复合增速更高（10.4% vs -8.1%）
Bioventus Inc.是一家全球化医疗技术企业，专注于骨科生物制剂领域，研发并商业化促进骨关节愈合、肌肉骨骼疼痛管理及再生护理的相关产品，服务全球多地的骨科临床医师、康复师及患者群体。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
BVS vs RBBN — 直观对比
营收规模更大
RBBN
是对方的1.0倍
$157.9M
营收增速更快
BVS
高出13.1%
-10.3%
净利率更高
RBBN
高出45.4%
9.3%
两年增速更快
BVS
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $157.9M | $162.6M |
| 净利润 | $14.8M | $89.1M |
| 毛利率 | 68.9% | 42.9% |
| 营业利润率 | 12.3% | 37.6% |
| 净利率 | 9.3% | 54.8% |
| 营收同比 | 2.8% | -10.3% |
| 净利润同比 | 3902.8% | — |
| 每股收益（稀释后） | $0.21 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BVSRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $157.9M | $227.3M | ||
| Q3 25 | $138.7M | $215.4M | ||
| Q2 25 | $147.7M | $220.6M | ||
| Q1 25 | $123.9M | $181.3M | ||
| Q4 24 | $153.6M | $251.4M | ||
| Q3 24 | $139.0M | $210.2M | ||
| Q2 24 | $151.2M | $192.6M |
净利润BVSRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $14.8M | — | ||
| Q3 25 | $3.2M | $-12.1M | ||
| Q2 25 | $7.5M | $-11.1M | ||
| Q1 25 | $-2.6M | $-26.2M | ||
| Q4 24 | $-388.0K | — | ||
| Q3 24 | $-5.2M | $-13.4M | ||
| Q2 24 | $-25.7M | $-16.8M |
毛利率BVSRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 68.9% | 53.3% | ||
| Q3 25 | 68.0% | 50.1% | ||
| Q2 25 | 69.1% | 49.6% | ||
| Q1 25 | 67.0% | 45.4% | ||
| Q4 24 | 66.8% | 55.7% | ||
| Q3 24 | 67.3% | 52.1% | ||
| Q2 24 | 68.5% | 50.8% |
营业利润率BVSRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | 12.3% | 4.1% | ||
| Q3 25 | 8.1% | 1.3% | ||
| Q2 25 | 12.4% | 1.9% | ||
| Q1 25 | 3.9% | -10.8% | ||
| Q4 24 | 5.0% | 13.2% | ||
| Q3 24 | 2.6% | -0.4% | ||
| Q2 24 | -20.8% | -1.0% |
净利率BVSRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | 9.3% | — | ||
| Q3 25 | 2.3% | -5.6% | ||
| Q2 25 | 5.1% | -5.0% | ||
| Q1 25 | -2.1% | -14.5% | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | -3.7% | -6.4% | ||
| Q2 24 | -17.0% | -8.7% |
每股收益（稀释后）BVSRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.21 | $0.50 | ||
| Q3 25 | $0.05 | $-0.07 | ||
| Q2 25 | $0.11 | $-0.06 | ||
| Q1 25 | $-0.04 | $-0.15 | ||
| Q4 24 | $0.00 | $0.05 | ||
| Q3 24 | $-0.08 | $-0.08 | ||
| Q2 24 | $-0.40 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.2M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.1M | $419.1M |
| 总资产 | $683.6M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BVSRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $51.2M | $96.4M | ||
| Q3 25 | $42.2M | $74.8M | ||
| Q2 25 | $32.9M | $60.5M | ||
| Q1 25 | $22.8M | $71.2M | ||
| Q4 24 | $41.6M | $87.8M | ||
| Q3 24 | $43.1M | $37.2M | ||
| Q2 24 | $32.0M | $64.6M |
总债务BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益BVSRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $184.1M | $449.0M | ||
| Q3 25 | $166.1M | $360.1M | ||
| Q2 25 | $161.2M | $370.4M | ||
| Q1 25 | $148.1M | $381.8M | ||
| Q4 24 | $147.9M | $404.6M | ||
| Q3 24 | $148.7M | $395.5M | ||
| Q2 24 | $150.9M | $405.0M |
总资产BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $683.6M | $1.2B | ||
| Q3 25 | $701.6M | $1.1B | ||
| Q2 25 | $706.8M | $1.1B | ||
| Q1 25 | $691.4M | $1.1B | ||
| Q4 24 | $728.0M | $1.2B | ||
| Q3 24 | $769.5M | $1.1B | ||
| Q2 24 | $792.2M | $1.1B |
负债/权益比BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.0M | — |
| 自由现金流经营现金流 - 资本支出 | $37.4M | — |
| 自由现金流率自由现金流/营收 | 23.7% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | $72.1M | — |
8季度趋势，按日历期对齐
经营现金流BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $38.0M | $29.2M | ||
| Q3 25 | $30.1M | $26.5M | ||
| Q2 25 | $25.9M | $-795.0K | ||
| Q1 25 | $-19.3M | $-3.5M | ||
| Q4 24 | $19.3M | $61.8M | ||
| Q3 24 | $10.3M | $-14.8M | ||
| Q2 24 | $15.2M | $-9.8M |
自由现金流BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | $37.4M | $27.3M | ||
| Q3 25 | $29.6M | $21.0M | ||
| Q2 25 | $25.3M | $-6.5M | ||
| Q1 25 | $-20.2M | $-15.7M | ||
| Q4 24 | $18.7M | $53.8M | ||
| Q3 24 | $10.3M | $-23.7M | ||
| Q2 24 | $15.1M | $-12.9M |
自由现金流率BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | 12.0% | ||
| Q3 25 | 21.4% | 9.7% | ||
| Q2 25 | 17.1% | -2.9% | ||
| Q1 25 | -16.3% | -8.7% | ||
| Q4 24 | 12.2% | 21.4% | ||
| Q3 24 | 7.4% | -11.3% | ||
| Q2 24 | 10.0% | -6.7% |
资本支出强度BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 0.9% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.7% | 6.7% | ||
| Q4 24 | 0.4% | 3.2% | ||
| Q3 24 | 0.0% | 4.2% | ||
| Q2 24 | 0.1% | 1.6% |
现金转化率BVSRBBN
| Q1 26 | — | — | ||
| Q4 25 | 2.57× | — | ||
| Q3 25 | 9.54× | — | ||
| Q2 25 | 3.48× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BVS
| Pain Treatments | $71.1M | 45% |
| Surgical Solutions | $48.9M | 31% |
| Restorative Therapies | $19.5M | 12% |
| Other | $18.4M | 12% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
